Peptide having skin condition improving activity and use thereof

Abstract

The present application relates to a peptide having a skin condition improving activity and a use thereof, and provides a peptide comprising the amino acid sequence of SEQ ID NO: 1 and a cosmetic composition for improving a skin condition comprising the peptide comprising the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

Description

Technical Field

[0001] This application relates to a peptide having skin condition improving activity and its use.

Background Art

[0002] Human skin undergoes continuous changes, and the most representative ones are the reduction of skin functions caused by aging and the decrease in visual beauty. Aging causes skin wrinkles, and as representative factors for forming wrinkles, exposure to ultraviolet rays and the reduction of collagen biosynthesis can be cited. Skin aging is roughly classified into endogenous aging caused by genetic factors and exogenous aging caused by external environmental factors such as sunlight. Among them, for exogenous aging, it is known that aging can be prevented, treated, or delayed by removing reactive oxygen species, proliferating fibroblasts, and promoting collagen biosynthesis.

[0003] Collagen, which is the main component of the extracellular matrix, is the main matrix protein produced in the fibroblasts of the skin. Collagen forms most of the organic substances in the skin, tendon, bone, and teeth, especially in high amounts in bone and skin (dermis). This collagen decreases due to age and photoaging caused by ultraviolet irradiation, which is known to be closely related to the formation of skin wrinkles. Also, collagen plays an important role in wound treatment, promoting collagen synthesis in damaged epithelium, thereby enabling rapid and complete wound recovery. In addition, it has been reported that as the biosynthesis of collagen is promoted and the density of the basal layer and the like becomes higher, the melanin concentration per unit skin density decreases, so a skin brightening effect can be expected.

[0004] Under this technical background, various studies are currently being conducted to improve skin condition through mechanisms such as promoting collagen biosynthesis, proliferating fibroblasts, etc. and enhancing activity (Korean Registered Patent No. 10-1813629), but they are still not perfect.

Summary of the Invention

[0005]

Technical Problem

[0006] On the one hand, a peptide consisting of the amino acid sequence of SEQ ID NO: 1 is provided.

[0007] On the other hand, a cosmetic composition for improving skin condition is provided, which comprises a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

[0008] Other objects and advantages of the present application will become more apparent in conjunction with the appended claims, the accompanying drawings, and the following detailed description. Regarding the content not described in this specification, as long as it can be fully recognized and analogized by those of ordinary skill in the art to which the present application belongs or those of ordinary skill in a similar technical field, the relevant description thereof is omitted.

[0009]

Technical Solution

[0010] The various descriptions and embodiments disclosed in the present application can also be applied to various other descriptions and embodiments. That is, all combinations of the various elements disclosed in the present application fall within the scope of the present application. Moreover, it is not determined that the scope of the present application is limited to the specific descriptions set forth hereinafter.

[0011] On the one hand, a peptide is provided, which consists of the amino acid sequence of SEQ ID NO: 1.

[0012] The term "peptide" used in this specification may refer to a linear molecule formed by amino acid residues bonded to each other through peptide bonds. The peptide can be prepared by chemical synthesis methods well known in the art, especially solid-phase synthesis techniques or liquid-phase synthesis techniques (US Registered Patent No. 5,516,891). As a result of efforts to develop peptides with biologically effective activities, the inventors have identified a peptide consisting of the amino acid sequence of SEQ ID NO: 1. Herein, the biologically effective activity may refer to (a) promoting the proliferation of fibroblasts or keratinocytes; (b) enhancing the expression of type I collagen (Col1a1), fibronectin, or elastin, which are extracellular matrix components; (c) enhancing the expression of the skin barrier factors, namely, silent information regulator 1 (SIRT-1) or aquaporin-3 (AQP3). Therefore, the peptide can be used for improving skin condition or antioxidation.

[0013] In the peptide, in order to obtain chemical stability, enhanced pharmacological properties (half-life, absorbability, potency, efficacy, etc.), altered specificity (e.g., a wide range of biological activities), and reduced antigenicity, a protecting group may be bound to the N- or C-terminus at the end of the peptide. In one embodiment, the N-terminus of the peptide may be bound to any one of the protecting groups selected from the group consisting of an acetyl group, a fluorenylmethoxycarbonyl group, a formyl group, a palmitoyl group, a myristyl group, a stearyl group, a butoxycarbonyl group, an allyloxycarbonyl group, and a polyethylene glycol (PEG); and / or the C-terminus of the peptide may be bound to any one of the protecting groups selected from the group consisting of an amino group (-NH2), a tertiary alkyl group, and a hydrazino group (-NHNH2). Further, the peptide may optionally further include a targeting sequence, a tag, a labeled residue, and an amino acid sequence prepared for a specific purpose of increasing the half-life or peptide stability.

[0014] The term "stability" used in this specification may refer not only to the in vivo stability that protects the peptide from the attack of proteolytic enzymes in the body but also to storage stability (e.g., room temperature storage stability).

[0015] On the other hand, a cosmetic composition for improving skin condition is provided, which includes a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

[0016] Among the terms or elements mentioned in the description of the peptide, the same content as that already mentioned is as described above.

[0017] The term "improvement" used in this specification may refer to all actions that at least alleviate parameters related to the alleviation or treatment of a condition, such as the degree of symptoms.

[0018] The term "skin condition improvement" used in this specification may refer to the process or effect of treating, alleviating, or mitigating skin damage caused by endogenous or exogenous skin factors, and may be interpreted, for example, as wrinkle improvement, skin elasticity improvement, wound recovery, skin barrier strengthening, or skin aging inhibition, but is not limited thereto.

[0019] Herein, "wrinkle improvement", "skin elasticity improvement", and "wound recovery" may refer to all actions that increase the total amount of extracellular matrix factors, including promoting collagen synthesis and the like. And, "skin barrier strengthening" may refer to strengthening the original function of the skin, that is, preventing the leakage of moisture and nutrients in the skin to the outside and preventing the invasion of harmful substances such as bacteria or viruses into the skin. And, "skin aging inhibition" may refer to inhibiting the reduction of skin functions such as wrinkles, skin sagging, and elasticity reduction. At this time, the skin aging may be photoaging, for example, skin aging caused by ultraviolet rays.

[0020] The disadvantages of existing functional peptides are that even if they have effective biological activities, they cannot be effectively introduced into target tissues or cells due to the size of the peptide itself, or they disappear from the body within a short time because of their short half-life. In contrast, according to an embodiment, a cosmetic composition includes a peptide composed of 10 or fewer amino acids as an active ingredient. Therefore, the skin permeability of the active ingredient is very excellent. For example, when locally applied to the skin, it can effectively improve the skin condition.

[0021] According to an embodiment, it can promote the proliferation of fibroblasts and keratinocytes and enhance the synthesis of extracellular matrix components and skin barrier factors. Therefore, the peptide can be used as an active ingredient of a cosmetic composition for improving skin condition.

[0022] The cosmetic composition may include a cosmetically effective amount of the peptide; and / or a cosmetically acceptable carrier, but is not limited thereto.

[0023] The term "cosmetically effective amount" used in this specification refers to an amount sufficient to achieve the skin condition improvement effect of the cosmetic composition.

[0024] The weight ratio between the peptide and the cosmetically acceptable carrier may be, for example, 500:1 to 1:500. For example, the weight ratio may be 450:1 to 1:450, 400:1 to 1:400, 350:1 to 1:350, 300:1 to 1:300, 250:1 to 1:250, 200:1 to 1:200, 150:1 to 1:150, 100:1 to 1:100, 80:1 to 1:80, 60:1 to 1:60, 40:1 to 1:40, 20:1 to 1:20, 10:1 to 1:10, 8:1 to 1:8, 6:1 to 1:6, 4:1 to 1:4, or 2:1 to 1:2, but is not limited thereto.

[0025] The cosmetic composition can be prepared into any dosage form commonly prepared in the art, for example, it can be prepared into a solution, suspension, emulsion, dough, gel, skin cream, skin lotion, powder, soap, surfactant-containing cleanser, oil, powder foundation, liquid foundation, wax foundation, and spray, etc., but not limited thereto. For example, the cosmetic composition can be prepared into a soft lotion, nutritious lotion, nutritious cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, facial mask, spray or powder dosage form.

[0026] When the dosage form of the cosmetic composition is dough, skin cream or gel, animal oil, vegetable oil, wax, paraffin wax, starch, tragacanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide, etc. can be used as carrier components.

[0027] When the dosage form of the cosmetic composition is foundation or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder can be used as carrier components. For example, if it is a spray, a propellant such as chlorofluorocarbon, propane / butane or dimethyl ether can be further included.

[0028] When the dosage form of the cosmetic composition is a solution or emulsion, a solvent, solubilizer or emulsifier can be used as carrier components. For example, it can include water, ethanol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol oil, glycerol fatty acid ester, polyethylene glycol or sorbitan fatty acid ester.

[0029] When the dosage form of the cosmetic composition is a suspension, a liquid phase diluent such as water, ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitan ester and polyoxyethylene sorbitan ester, microcrystalline cellulose, aluminum hydroxide methyl, bentonite, agar or tragacanth, etc. can be used.

[0030] When the dosage form of the cosmetic composition is a surfactant-containing cleanser, fatty alcohol sulfate, fatty alcohol ether sulfate, sulfosuccinic acid monoester, hydroxyethyl sulfonate, imidazoline derivative, methyl taurate, sarcosinate, fatty acid amide ether sulfate, alkylamide betaine, fatty alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative or ethoxylated glycerol fatty acid ester, etc. can be used as carrier components.

[0031] The peptide may be included in a nanobody or nanoparticle to further improve skin penetration or stability issues. For example, the nanobody can be prepared using a microfluidizer with lecithin as a raw material and can be included in lecithin particles. As a method for preparing the nanobody, any well-known method can be used. The size of the nanobody particles is preferably 30 to 200 nm. When the size of the nanobody particles is less than 30 nm, skin penetration may be very fast, leading to skin side effects. When the size of the nanobody particles is greater than 200 nm, it may not easily penetrate the skin, making it difficult to obtain the usage effect of the nanobody.

[0032] In addition to the peptide as the active ingredient and the carrier component, the components included in the cosmetic composition include conventional components for cosmetic compositions, such as conventional adjuvants like antioxidants, stabilizers, solubilizers, vitamins, pigments, and fragrances.

[0033] The content of the peptide as the active ingredient included in the cosmetic composition can be appropriately and non-restrictively selected according to the product form, desired use, etc. For example, it can be added in an amount of 0.01 to 15% by weight of the total weight of the cosmetic composition. And, for example, the cosmetic composition can include 1.0% to 3.0% by weight, preferably 2.0% to 3.0% by weight of the peptide based on the total weight.

[0034] On the other hand, there is provided a method for improving skin condition, which includes the step of applying a cosmetic composition including a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient to the skin of an individual; and the use of the peptide consisting of the amino acid peptide of SEQ ID NO: 1 in the preparation of a composition for improving skin condition.

[0035] Among the terms or elements mentioned in the description of the cosmetic composition, the same content as that already mentioned is as described above.

[0036] In the terms used in this specification, the "individual" refers to an object in need of improving skin condition. More specifically, it refers to mammals such as humans or non-human primates, mice, dogs, cats, horses, and cows.

[0037] In the terms used in this specification, "application", "administration", and "coating" can be used interchangeably and can refer to localizing at least part of the composition according to an embodiment at a desired site, or disposing the composition according to an embodiment within an individual through an administration route.

[0038] On the other hand, there is provided an antioxidant composition, which includes a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

[0039] Among the terms or elements mentioned in the description of the peptide, the same content as that already mentioned is as described above.

[0040] The antioxidant composition may be in the form of a pharmaceutical composition, a quasi-drug composition, or a cosmetic composition. As an example, the composition may be used as a cosmetic composition for improving skin conditions, or a pharmaceutical composition for improving or treating disease states related to skin damage.

[0041] According to one embodiment, it is shown that the peptide can restore the reduced activity of fibroblasts or keratinocytes and enhance their antioxidant efficacy. Therefore, the peptide can be used as an active ingredient of the antioxidant composition.

[0042] As an example, the antioxidant composition may be provided in the form of a pharmaceutical composition. The pharmaceutical composition may include a pharmaceutically effective amount of the peptide; and / or a pharmaceutically acceptable carrier, but is not limited thereto.

[0043] The term "pharmaceutically effective amount" used in this specification may refer to the amount of the pharmaceutical composition sufficient to achieve the prophylactic or therapeutic efficacy against diseases related to skin damage.

[0044] The pharmaceutically acceptable carrier is commonly used in preparation and includes lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum arabic, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylparaben, propylparaben, talc, magnesium stearate, and mineral oil, etc., but is not limited thereto. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington′s Pharmaceutical Sciences (19th ed., 1995).

[0045] The weight ratio between the peptide and the pharmaceutically acceptable carrier may be, for example, from 500:1 to 1:500. As an example, the weight ratio may be from 450:1 to 1:450, from 400:1 to 1:400, from 350:1 to 1:350, from 300:1 to 1:300, from 250:1 to 1:250, from 200:1 to 1:200, from 150:1 to 1:150, from 100:1 to 1:100, from 80:1 to 1:80, from 60:1 to 1:60, from 40:1 to 1:40, from 20:1 to 1:20, from 10:1 to 1:10, from 8:1 to 1:8, from 6:1 to 1:6, from 4:1 to 1:4, or from 2:1 to 1:2, but is not limited thereto.

[0046] In addition to the above-mentioned components, the pharmaceutical composition may further include lubricants, wetting agents, sweeteners, flavoring agents, emulsifying agents, suspending agents, preservatives, etc., but not limited thereto.

[0047] The pharmaceutical composition can be administered enterally or parenterally, preferably parenterally. For parenteral administration, it can be administered by intramuscular injection, intravenous injection, subcutaneous injection, intraperitoneal injection, topical administration, transdermal administration, etc., but not limited thereto.

[0048] The dosage of the pharmaceutical composition can be 0.0001 to 1000 μg (micrograms) per day, 0.001 to 1000 μg, 0.01 to 1000 μg, 0.1 to 1000 μg, or 1.0 to 1000 μg, but not limited thereto, and can be differently prescribed according to factors such as the formulation method, administration mode, age, weight, gender, medical condition, diet, administration time, administration route, excretion rate, and reaction sensitivity of the patient.

[0049] The pharmaceutical composition can be formulated into a unit volume form by using pharmaceutically acceptable carriers and / or excipients according to methods easily implemented by those of ordinary skill in the technical field to which the present invention pertains, or can be prepared by injecting it into a multi-volume container.

[0050] The dosage form can be in the form of a solution, suspension, or emulsion in an oily or aqueous solvent, can also be in the form of an extractant, powder, granule, lozenge, or capsule, and can further include a powder and / or stabilizer.

[0051] On the other hand, a food composition for improving skin condition is provided, which includes a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

[0052] Among the terms or elements mentioned in the description of the peptide, the same content as that already mentioned is as described above.

[0053] The content of the peptide as the active ingredient included in the food composition can be appropriately and non-restrictively selected according to the food form, desired use, etc. For example, it can be added at 0.01 to 15% by weight of the total weight of the food. For example, for a health beverage composition, based on 100 ml, it can be added at a ratio of 0.02 to 10 g, preferably 0.3 to 1 g.

[0054]

Beneficial effects

[0055] A peptide according to one aspect can promote the proliferation of fibroblasts and keratinocytes and enhance the synthesis of extracellular matrix components and skin barrier factors, and thus can be applied to the improvement of skin conditions, including wrinkle improvement, skin elasticity improvement, wound healing, skin barrier strengthening, or skin aging inhibition, etc.

[0056] Therefore, the peptide according to one aspect can be used as an active ingredient of a composition for improving skin conditions.

BRIEF DESCRIPTION OF THE DRAWINGS

[0057] Figure 1 It shows the results of confirming the cell proliferation level after adding the peptide composed of the amino acid sequence of SEQ ID NO: 1 to skin cells. Among them, Figure 1 A of shows the results of changes in the viability of NIH3T3 cells, Figure 1 B of shows the results of changes in the viability of HaCaT cells.

[0058] Figure 2 It shows the results of increased expression of extracellular matrix components, namely type I collagen (Col1a1), fibronectin, and elastin, after adding the peptide composed of the amino acid sequence of SEQ ID NO: 1 to NIH3T3 cells.

[0059] Figure 3 It shows the quantitative evaluation of the expression levels of extracellular matrix components after adding the peptide composed of the amino acid sequence of SEQ ID NO: 1 to NIH3T3 cells. Among them, Figure 3 A of shows the results of confirming the expression level of Col1a1, Figure 3 B of shows the results of confirming the expression level of fibronectin, Figure 3 C of shows the results of confirming the expression level of elastin.

[0060] Figure 4 It shows the results of increased expression of skin barrier factors, namely sirtuin 1 (SIRT-1) and aquaporin 3 (AQP3), after adding the peptide composed of the amino acid sequence of SEQ ID NO: 1 to HaCaT cells.

[0061] Figure 5 It shows the quantitative evaluation of the expression levels of skin barrier factors after adding the peptide composed of the amino acid sequence of SEQ ID NO: 1 to HaCaT cells. Among them, Figure 5 A of shows the results of confirming the expression level of SIRT-1, Figure 5 B of shows the results of confirming the expression level of AQP3.

[0062] Figure 6The results of quantitatively confirming the change in the level of reactive oxygen species increased by ultraviolet rays after adding the peptide consisting of the amino acid sequence of SEQ ID NO: 1 to NIH3T3 cells are shown.

[0063] Figure 7 The results of quantitatively confirming the change in the level of reactive oxygen species increased by ultraviolet rays after adding the peptide consisting of the amino acid sequence of SEQ ID NO: 1 to HaCaT cells are shown.

Detailed Description of the Invention

[0064] Hereinafter, the present invention will be described in more detail by way of examples. However, these examples are only used to exemplarily describe the present invention, and the scope of the present invention is not limited to these examples.

[0065]

Example 1: Synthesis of Peptide

[0066] A peptide having the amino acid sequence of SEQ ID NO: 1 described in Table 1 below was synthesized using an automatic peptide synthesizer (Milligen 9050, Millipore, USA), and the synthesized peptide was purified by C18 reversed-phase high performance liquid chromatography (HPLC) (Waters Associates, USA). ACQUITY UPLC BEH300 C18 (2.1 mm × 100 mm, 1.7 μm, Waters Co, USA) was used as the column.

[0067]

Table 1

[0068] SEQ ID NO Sequence (N-terminus → C-terminus) 1 DGWNY

[0069]

Example 2: Confirmation of the Effect of Promoting Proliferation of Skin Cells

[0070] This example aims to confirm the effect of the peptide according to an embodiment on the proliferation of skin cells by evaluating the change in the viability of mouse fibroblasts, namely NIH3T3 cells, or human keratinocytes, namely HaCaT cells.

[0071] Specifically, NIH3T3 cells or HaCaT cells were seeded at 5×10 3The cells were seeded at a density of cells / well in a 96-well plate and then cultured for 24 hours. Then, the cells were washed once with serum-free DMEM media. The peptide consisting of the amino acid sequence of SEQ ID NO: 1 was aliquoted at 50 μM or 100 μM into 200 μL of the serum-free media, and it was cultured in a CO2 incubator at 37 °C for 72 hours. Then, after washing the culture twice with PBS, the MTT (Sigma, Cat. No: M2003, USA) solution was aliquoted into each well at 0.5 mg / ml. Then, after shielding from light, it was cultured in a CO2 incubator at 37 °C for 4 hours. Then, the absorbance at 540 nm was measured. In this example, the control group was the untreated group, and the group supplemented with insulin-like growth factor (IGF) was used as the positive control group.

[0072] As a result, it was confirmed that Figure 1 as shown, the peptide consisting of the amino acid sequence of SEQ ID NO: 1 promoted the proliferation of fibroblasts and keratinocytes.

[0073]

Example 3: Confirmation of wrinkle improvement and elasticity enhancement effects

[0074] This example aimed to confirm the effect of the peptide according to an example on improving endogenous skin aging including wrinkle improvement and elasticity enhancement by evaluating the expression levels of type I collagen (Col1a1), fibronectin, or elastin, which are known as dermal components.

[0075] Specifically, NIH3T3 cells were seeded at a density of 3×10 5 cells / well in a 6-well plate and cultured for 24 hours. Then, after washing the cells once with serum-free DMEM media, the peptide consisting of the amino acid sequence of SEQ ID NO: 1 was aliquoted at 50 μM or 100 μM into the 1 mL of media, and it was cultured in a CO2 incubator at 37 °C for 24 hours. Then, after washing the culture twice with PBS, easy blue (iNtRON, Korea) was used to isolate ribonucleic acid (RNA) from the culture. Reverse transcription was performed on 1 μg of the isolated RNA using an RT kit (Enzynomics, Korea) to synthesize each complementary deoxyribonucleic acid (cDNA). Then, polymerase chain reaction (PCR) was performed using the cDNA and Col1a1, fibronectin, and elastin primers. The control group was the untreated group, and the group supplemented with TGF-β1 (TGF-β1) was used as the positive control group. The nucleotide sequences of the primers used in this example are shown in Table 2 below.

[0076]

Table 2

[0077]

[0078] As a result, it was confirmed that, as shown in Figure 2 and 3 the expression levels of extracellular matrix components, namely Colla1, fibronectin, and elastin, increased through the peptide composed of the amino acid sequence of SEQ ID NO: 1. From the above results, it was found that the peptide according to one embodiment contributes to the improvement of endogenous skin aging, including wrinkle improvement and elasticity enhancement, by increasing extracellular matrix components.

[0079]

Example 4: Confirmation of Skin Barrier Strengthening Effect

[0080] This example aims to confirm the effect of the peptide according to one embodiment on skin barrier strengthening by evaluating the expression levels of sirtuin 1 (SIRT-1) or aquaporin 3 (AQP3).

[0081] Specifically, HaCaT cells were seeded in a 6-well plate at a density of 3×10 5 cells / well and cultured for 24 hours. Then, after washing the cells once with serum-free DMEM media, the peptide composed of the amino acid sequence of SEQ ID NO: 1 was added to the 1 mL of the medium at 50 μM or 100 μM, and the mixture was cultured in a CO2 incubator at 37°C for 24 hours. Then, after washing the culture twice with PBS, ribonucleic acid (RNA) was isolated from the culture using easy blue (iNtRON, Korea). Complementary deoxyribonucleic acid (cDNA) was synthesized by reverse-transcribing 1 μg of the isolated RNA using an RT kit (Enzynomics, Korea). Then, polymerase chain reaction was performed using the cDNA and primers for sirtuin-1 and aquaporin-3. The control group was the untreated group, and the group supplemented with EGF (EGF) was used as the positive control group. The nucleotide sequences of the primers used in this example are shown in Table 3 below.

[0082]

Table 3

[0083]

[0084] As a result, it was confirmed that, as shown in Figure 4 and Figure 5As shown, the expression of SIRT-1 and AQP3, which are skin barrier factors, increased through the peptide composed of the amino acid sequence of SEQ ID NO: 1. From the above results, it can be seen that the peptide according to one embodiment contributes to skin barrier strengthening and skin anti-aging by increasing skin barrier factors.

[0085]

Example 5: Confirmation of the effect of reducing reactive oxygen species increased by ultraviolet rays

[0086] This example aims to confirm the antioxidant effect of the peptide according to one embodiment on damaged skin cells by evaluating the change in the level of reactive oxygen species in skin cells increased by ultraviolet irradiation.

[0087] Specifically, NIH3T3 cells or HaCaT cells were seeded in a 6-well plate at a density of 5×10 5 cells / well and then cultured for 24 hours. Then, after washing the cells once with serum-free DMEM media, the peptide composed of the amino acid sequence of SEQ ID NO: 1 was aliquoted into the 1 mL of the medium at 50 μM or 100 μM, and it was cultured in a CO2 incubator at 37 °C for 1 hour. Then, the culture was transferred to an e-tube, mixed with 1 mL of PBS, and aliquoted into a well plate. Then, NIH3T3 cells were irradiated with 8 J / cm 2 of ultraviolet rays using a UV irradiator (VILBER LOURMAT, France), and HaCaT cells were irradiated with 15 mJ / cm 2 of ultraviolet rays. Then, the PBS in the well plate was removed, 900 μL of the medium aliquoted with the peptide was added, and it was cultured in a CO2 incubator at 37 °C for 24 hours. Then, the culture was treated with 2′,7′-dichlorofluorescin diacetate (DCFH-DA), wrapped with foil, and cultured in a CO2 incubator at 37 °C for 30 minutes. Then, after washing twice with PBS, 500 μL of 1× trypsin / ethylenediaminetetraacetic acid (EDTA) was used to obtain the cells, and then centrifuged. The centrifuged cells were washed with PBS, and the fluorescence value was measured using a flow cytometer (FACS, BD, USA). In this example, the control group was the untreated group, the comparison group (NC) was the group irradiated only with ultraviolet rays, and the group added with 50 μM of Trolox (Trolox) was used as the positive control group.

[0088] As a result, it was confirmed as Figure 6 and 7As shown, the level of reactive oxygen species in fibroblasts and keratinocytes increased by ultraviolet irradiation was reduced by the peptide consisting of the amino acid sequence of SEQ ID NO: 1. From the above results, it can be seen that the peptide according to an embodiment contributes to the antioxidant effect of skin cells induced by ultraviolet rays.

[0089]

Formulation Example 1: Preparation of Peptide Nanobody

[0090] 50 mg of the peptide of Example 1 was dissolved by sufficiently stirring with 500 ml of distilled water. After mixing the complex solution with 5 g of lecithin, 0.3 ml of sodium oleate, 50 ml of ethanol and a small amount of oil phase, the volume was adjusted to 1 L with distilled water, and then emulsified under high pressure using a high-pressure microfluidizer to prepare a peptide nanobody with a size of about 100 nm.

[0091]

Formulation Example 2: Soft Lotion

[0092] A soft lotion containing the peptide according to an embodiment and having the following composition was prepared by a method well known in the art.

[0093]

Table 4

[0094] Ingredient Content (wt%) Peptide 1.0 1,3-Butanediol 6 Glycerin 4 Polyethylene Glycol 1500 1 Sodium Hyaluronate 1 Polysorbate 20 0.5 Ethanol 8 Benzophenone-9 0.05 Preservative, pigment Appropriate amount Fragrance Appropriate amount Purified water Balance Total 100

[0095]

Formulation Example 3: Nutritional Cream

[0096] A nutritional cream containing the peptide according to an embodiment and having the following composition was prepared by a method well known in the art.

[0097]

Table 5

[0098]

[0099]

[0100]

Formulation Example 4: Nutritional Lotion

[0101] A nutritional lotion containing the peptide according to an embodiment and having the following composition was prepared by a method well known in the art.

[0102]

Table 6

[0103] Ingredient Content (wt%) Peptide 3.0 1,3-Butanediol 4 Glycerin 4 Cetearyl Alcohol 0.8 Glyceryl Stearate 1 Triethanolamine 0.13 Tocopheryl Acetate 0.3 Liquid Paraffin 5 Squalene 3 Oil 2 Polysorbate 60 1.5 Sorbitan Sesquioleate 0.5 Carboxyvinyl Polymer 1 Preservative, pigment Appropriate amount Fragrance Appropriate amount Purified water Balance Total 100

[0104]

Formulation Example 5: Serum

[0105] A serum containing the peptide according to an embodiment and having the following composition was prepared by a method well known in the art.

[0106]

Table 7

[0107]

[0108]

[0109] The description of the present invention is only for providing examples, and those of ordinary skill in the art should be able to understand that the present invention can be easily modified into other specific forms without changing the technical idea or essential features of the present invention. Therefore, the embodiments described above should be understood as exemplary in all aspects and not restrictive.

Claims

1. A peptide consisting of the amino acid sequence of SEQ ID NO:

1.

2. The peptide according to claim 1, wherein, The N-terminus of the peptide is bound to any one of the protecting groups selected from the group consisting of acetyl, fluorenylmethyloxycarbonyl, formyl, palmitoyl, myristoyl, stearoyl, butoxycarbonyl, allyloxycarbonyl, and polyethylene glycol.

3. The peptide according to claim 1, wherein The C-terminus of the peptide is bound to any one of the protecting groups selected from the group consisting of amino, tertiary alkyl, and hydrazino.

4. The peptide according to claim 1, wherein, The peptide exhibits at least any one of the following characteristics: (a) Promoting the proliferation of fibroblasts or keratinocytes; (b) Enhancing the expression of type I collagen, fibronectin, or elastin, which are components of the extracellular matrix; (c) Enhancing the expression of silent information regulator-1 or aquaporin-3, which are skin barrier factors.

5. A cosmetic composition for improving skin condition, comprising the peptide according to any one of claims 1 to 4 as an active ingredient.

6. The cosmetic composition according to claim 5, wherein, The peptide is prepared in the form of a nanobody.

7. The cosmetic composition according to claim 5, wherein, The improvement of the skin condition is improvement of wrinkles, improvement of skin elasticity, wound healing, strengthening of the skin barrier, or inhibition of skin aging.

8. The cosmetic composition according to claim 7, wherein The skin aging is skin aging caused by ultraviolet rays.

Images